Form 4: HilleVax Director Aditya Kohli Sells Shares Under 10b5-1 Trading Plan

Sentiment:

SEC Form 4


Director Aditya Kohli of HilleVax, Inc. executed sales of common stock between March 18 and March 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • Aditya Kohli, a director at HilleVax, Inc., sold 6,000 shares of common stock on each of the following dates: March 18, 2024, March 19, 2024, and March 20, 2024.
  • The sales were executed under a Rule 10b5-1 trading plan adopted on October 12, 2023.
  • The weighted average sale prices were $17.6561 on March 18, $17.4153 on March 19, and $164,221 on March 20.
  • Following these transactions, Kohli directly owns 807,776 shares of HilleVax, Inc.
  • The filing was signed by Paul Bavier, Attorney-in-Fact for Aditya Kohli, on March 20, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider trading activity. It's common for executives and directors to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

  • The stock sales by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in investor confidence.
  • However, the existence of a pre-arranged trading plan mitigates concerns about insider trading based on non-public information.

Key Dates

DateDescription
2023-10-12Date of adoption of Rule 10b5-1 trading plan
2024-03-18First transaction date: Sale of 6,000 shares at a weighted average price of $17.6561
2024-03-19Second transaction date: Sale of 6,000 shares at a weighted average price of $17.4153
2024-03-20Third transaction date: Sale of 6,000 shares at a weighted average price of $164,221
2024-03-20Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.